Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for patients at clinical high risk of psychosis
ISRCTN10334895Phase 2Completed
- Sponsor
- King's College London
- Start
- Sep 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Clinical high risk for psychosis (CHR) and attenuated psychosis syndrome (APS) comparing Cannabidiol + treatment as usual with Placebo + treatment as usual (2 arms). Started Sep 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
Clinical high risk for psychosis (CHR)attenuated psychosis syndrome (APS)
Beyond the preview
Go deeper on ISRCTN10334895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10334895.